War Torn Labz SARM's MK2866 and MK677 STACK 60 CAPS

£54.95

War Torn Labz have lead the way in the UK regarding SARMs and are expanding their bodybuilding supplement range.

With this recent addition of MK2866 (Ostarine) and MK677 (Ibutamoren) Selective Androgen Receptor Modulator dietary supplement combined together we have a great potent combination.

Additionally, a previous clinical study showed that the 3 mg dose of enobosarm resulted in larger improvements in lean body mass and physical function in healthy older men and postmenopausal women as compared with the 1 mg dose.

Ostarine or MK2866 has been used for its ability to repair muscle damage incredibly quickly without the negative effects of Anabolic Steroids. So as long as you're putting the effort in this will repair you and get your muscular gains super fast.

The MK-677 or Ibutamoren is not actually a SARM (selective androgen receptor modulator, it is something called a secretagogue which burns fat, increases growth hormone and insulin growth factor 1 IGF-1 massively. MK677 as shown to improve quality of sleep dramatically.

POTENTIAL BENEFITS OF WAR TORN LABZ MK-2866 & MK-677

MK677 10MG
MK2866 10MG
BETTER SLEEP
INCREASED SIZE
IMPROVED PHYSICAL FUNCTION
INCREASED LEAN BODY MASS
POWERFUL ANABOLIC AGENT
RAPID WEIGHT LOSS
VEGGIE CAPSULES, HALAL CERTIFIED
SOURCED IN THE UNITED STATES

MK-2866 or ostarine

is one of the most known of all the SARM's and minimal Adverse effects, with improved physical function and increased lean body mass.

MK-2866 was also used in the treatment of muscle wasting and improving lean body mass in patients.

MK-677 Ibutamoren

a well know secretagogue used by the bodybuilding community to reduce body fat and increase lean body mass at the same time. This improvement in Skeletal muscle mass , lean body mass and Physical function is due to its ability to release Growth Hormone and IGF-1.

The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial .

Some technical research on MK-677 & MK-2866

MK-2866 was also used in the treatment of muscle wasting and improving lean body mass in patients.

Another clinical study showed the Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial - PMC

Patients with muscle wasting commonly present with fatigue, weight loss, and reduced physical function, which can contribute to disability, reduced quality of life, and shorter overall survival compared with patients without muscle loss.

Secondary objectives were assessment of the effects of enobosarm on total bodyweight, physical function (stair climb, 6 m walk, grip test), bone turnover markers, total body fat mass, hair growth, prostate-specific antigen, haemoglobin, appetite, quality of life (assessed by Functional Assessment of Anorexia/Cachexia Therapy score [FAACT] and Functional Assessment of Chronic Illness Therapy-Fatigue [FACIT-F]), and inflammation markers.

Although this association might be true for survival and overall quality of life, we are not aware of data suggesting that supportive care alone leads to improvements in lean body mass and physical function.

Age, BMI, and lean body mass at baseline did not differ between those in the evaluable efficacy population and those not (p>0·70 for all comparisons); however, participants assigned placebo in the evaluable efficacy population population had a tendency toward higher baseline physical function (p=0·094) with median power of 77 watts versus 66 watts, possibly suggesting that those patients were more fit at baseline and were more likely to complete the study.Cancer-induced muscle wasting is a highly prevalent and potentially severe disorder that can adversely affect treatment outcomes, quality of life, and mortality.

Cancer and SARMS

If enobosarm shows activity that is better than the endocrine therapy of physician's choice as an active control, this will become an important treatment modality in our armamentarium.

The prevalence of muscle wasting in cancer patients increases to greater than 80% prior to death from malignancy and represents the cause of death in over 20% of cancer patients [13–16].

Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Cancer - Full Text View - ClinicalTrials.gov

Read our disclaimer ClinicalTrials.gov Identifier: NCT04869943 First Posted : May 3, 2021 Study Details Tabular View No Results Posted Disclaimer How to Read a Study Record To demonstrate the efficacy of enobosarmin the treatment of androgen receptor positive (AR+) and estrogen receptor positive (ER+) metastatic breast cancer (MBC) as measured by radiographic progression free survival (rPFS).

Exemestane monotherapy, exemestane plus everolimus, or selective estrogen receptor modulator (SERM) To demonstrate the efficacy of Enobosarm in the treatment of androgen receptor positive (AR+) and estrogen receptor positive (ER+) metastatic breast cancer (MBC) as measured by radiographic progression free survival (rPFS). [ Time Frame: Day 120 ] The primary endpoint for the study is the median radiographic progression free survival (rPFS) in the Enobosarm Treatment Group compared to the Control Treatment Group.

SARMS ARE FOR RESEARCH PURPOSES ONLY. THIS PRODUCT IS NOT A NUTRITIONAL SUPPLEMENT, NOR A FOOD AND SHOULD NOT BE USED AS ONE. THIS PRODUCT IS SOLELY FOR RESEARCH PURPOSES ONLY.